Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2

Status

Active not recruiting 21Recruiting 17Completed 17Withdrawn 6Terminated 5Unknown 4Not yet recruiting 2Suspended 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 6

Conditions

Carcinoma, Non-Small-Cell Lung 14Lung Neoplasms 6Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Carcinoma, Renal Cell 2Uveal Melanoma 1Squamous Non-small Cell Lung Cancer 1Small Cell Lung Carcinoma 1Primary Myelofibrosis 1Polycythemia Vera 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Microsatellite Instability 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Liver Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Breast Cancer Female 1Biliary Tract Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma Of Esophagus 1

Interventions

Carboplatin 18Radiotherapy 10Cisplatin 10Pemetrexed 8Paclitaxel 8durvalumab 6Magnetic Resonance Spectroscopy 6Gemcitabine 6Radiosurgery 5Nivolumab 5Etoposide 5pembrolizumab 4atezolizumab 4Surveys and Questionnaires 4Radiation 4Erlotinib Hydrochloride 4Docetaxel 4Taxes 3Standard of Care 3Specimen Handling 3Platinum 3Cetuximab 3Bronchoscopy 3Biopsy 3Bevacizumab 31,2-diaminocyclohexaneplatinum II citrate 3sapanisertib 2etoposide phosphate 2capmatinib 2Vinorelbine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Withdrawn × Lung Neoplasms × durvalumab × Clear all
NCT05358691 2025-04-16

A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

Rutgers, The State University of New Jersey

Phase 1 Withdrawn
Thoracic

Lung Neoplasms

NCT04944173 2024-09-03

SCION

University of British Columbia

Phase 2 Withdrawn
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm, Residual

NCT05848843 2024-01-23

A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Thoracic

Lung Neoplasms

NCT05161533 2023-10-18

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

University of Washington

Phase 2 Withdrawn
Thoracic

Lung Neoplasms

NCT04470674 2022-03-03

Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

Hoosier Cancer Research Network

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04262869 2021-10-27

Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer

Emory University

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡